Elliott Sigal, M.D., Ph.D.
Elliott is a renowned scientific and industry leader who recently served on the board of gene therapy pioneer Spark Therapeutics for five years. During that time, the company developed and launched Luxturna®, the first AAV gene therapy
in the United States, and was acquired by Roche for $4.3 billion. Elliott is a former executive vice president and director of Bristol Myers Squibb (BMS), where he also served as chief scientific officer and president of research and
development (R&D). Under Elliott’s leadership at BMS, 14 new medicines were approved and Scrip Intelligence named him the best R&D chief in the pharmaceutical industry in 2012. Elliott serves as a senior adviser to the healthcare team
of New Enterprise Associates (NEA). He is a board member of Alnylam Pharmaceuticals, Inc., Adaptimmune, Surface Oncology, and Vir Biotechnology. He co-chairs Amgen’s Scientific Advisory Board and is a member of the Scientific Steering
Committee for the Parker Institute for Cancer Immunotherapy (PICI). Elliott received a B.S., M.S., and Ph.D. in industrial engineering from Purdue University and an M.D. from the University of Chicago.